Recordati SpA (Recordati) develops, manufactures, and commercializes drugs for primary care and orphan drugs for the treatment of rare diseases. It provides a range of pharmaceuticals, proprietary and under license, for various disease conditions, including a specialized segment committed to treating rare diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on developing new specialties originating either internally or acquired through development agreements with other pharmaceutical companies and research institutes. Recordati is engaged in research and development of new drugs, with a particular focus on rare diseases. Recordati has its own facilities for the production of pharmaceutical and chemical products. The company is committed to the early-stage design of clinical trials and research and development, focusing on involving patient associations and patient feedback. Recordati collaborates with universities worldwide to develop new therapeutic uses for current treatments and promote research and development in areas such as metabolic diseases, endocrinology, and oncology. The company's commitment, scientific rigor, capability, and highly specialized personnel enable the development of new treatments and the building of an innovative product pipeline. Recordati SpA's R&D units include CMC, preclinical, regulatory, patient safety, QA, clinical operations, clinical development, and medical affairs, each playing a crucial role in managing the company's R&D activities. The company is focused on developing new specialities and treatments and investing in medical innovations for a brighter future. In FY2025, the company spent EUR340.9 million on its R&D activities, which as a percentage of revenue stood at 13%, and grew 16.1% YoY.